The first biotech IPO in a month, Electra&#x27;s upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week podcast, BioCentury&#x27;s analysts examine momentum in the biotech IPO market. The team also unpacks fatal toxicities in Novartis&#x27; autoimmune CAR-T trials and what they reveal about manufacturing, dosing and immune biology risks across the modality. In Washington, Steve Usdin previews Heidi Overton&#x27;s FDA Commissioner confirmation hearing and reports on the persistent uncertainty around pharma tariffs ahead of the Sept. 29 deadline. View full story: https://www.biocentury.com/article/660870 #BiotechIPO #CARTCell #FDA #PharmaTariffs #DrugDevelopment 0:00 Introduction 02:15 Biotech IPO Market 10:38 Autoimmune CAR-T Safety 21:56 FDA Commissioner Hearing 26:47 Pharma Tariff Uncertainty To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

BioCentury This Week

[SPEAKER_05] The first biotech IPO on NASDAQ in more than a month, upsized and fell in its first day of trading. We check in on the state of biotech IPOs on the BioCentury This Week podcast. Plus, fatal toxicities are testing autoimmune CAR T's safety thesis. And there's a handful of days to go and pharma tariff rules are a total mystery.

[SPEAKER_05] What's not a mystery is which biotechs will be most affected. And Heidi Overton, the White House pick for FDA Commissioner, is getting her day before the HELP Committee. It's a little sooner than we expected. We'll discuss. Joining me on today's BioCentury This Week podcast, Paul Bananos, our news editor, Steve Usdin, our Washington editor, Selina Koch, executive editor, and Lauren Martz, who heads up

[SPEAKER_05] our product development coverage. I'm Jeff Cranmer, host of the BioCentury This Week podcast. Before we get into today's episode, a quick heads up. Last week, episode 387, psychedelics at FDA, Mike Davis's CEDAR and tRNAs had an upload error where an earlier episode

[SPEAKER_05] briefly showed up in its place. We caught it early, thanks to one of our listeners who used fan mail to point this out to us. Our production engineer quickly fixed it. But if you missed the episode, it's there for you now. Or if you downloaded that episode on Apple Podcasts before it got fixed, you might just need to delete the download and grab it again to get the corrected version.

[SPEAKER_05] And hey, fan mail. It's a good thing. It's a little text link in our show notes where you can send the BioCentury This Week team a message. So if you have a question or want to give us a shout out, hopefully we don't have too many more technical errors...

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.